Log in  First Connection?
  
EnglishJapaneseFrenchSpanishGerman

Blood CancerArchives

Effectiveness of venetoclax based therapy in t(11;14) multiple myeloma with extensive extramedullary disease: a case report
Blood Cancer
 2 min.

 Published on 16/09/2025 |  Original article (Full-text)  | Brinkert Kerstin et al. | Annals of Hematology 2025; 104(8): 4223-7

Multiple myeloma (MM) is a monoclonal plasma cell disorder and is the second most frequent haematological cancer after lymphomas. It primarily affects the bone marrow and is characterised by the presence of monoclonal protein in the serum and/or urine, along with systemic symptoms such as anaemia, bone...

HTML version PDF version  Print abstract

Methods for the analysis of leukemic infiltration within cerebrospinal fluid in acute lymphoblastic leukemia—a systematic review
Blood Cancer
 1 min.

 Published on 09/09/2025 |  Original article (Full-text)  | Lavleen Singh a et al. | Leukemia & Lymphoma 2025; aop:10.1080/10428194.2025.2550580

Central nervous system (CNS) involvement in acute lymphoblastic leukemia (ALL) is associated with a poor prognosis, making its accurate detection vital for treatment planning. This systematic review critically examines the role of conventional cytomorphology (CC) and multiparameter flow cytometry (FC)...

HTML version PDF version  Print abstract

The role of maintenance therapy and its cessation in patients with multiple myeloma
Blood Cancer
 1 min.

 Published on 02/09/2025 |  Original article (Full-text)  | Abigail P. Sneider et al. | Leukemia & Lymphoma 2025; aop:10.1080/10428194.2025.2551785

Lenalidomide maintenance therapy remains a cornerstone of post-induction treatment in multiple myeloma (MM), supported by various landmark trials demonstrating improved outcomes with lenalidomide maintenance over observation or placebo following autologous stem cell transplant (ASCT). Despite advancements...

HTML version PDF version  Print abstract

Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition
Blood Cancer
 7 min.

 Published on 26/08/2025 |  Original article (Full-text)  | Sabol Hayley M. et al. | Experimental Hematology & Oncology 2025; 14(1): 108

Multiple myeloma (MM) is the second most common hematologic cancer in the United States [1], characterized by the clonal proliferation of malignant plasma cells within the bone marrow [2]. Bone disease is a hallmark of MM, affecting 80% of newly diagnosed patients [3] and contributes significantly to...

HTML version PDF version  Print abstract

Proceedings of the 4th European Congress controversies in Leukemias, held in Brussels, Belgium, 20-21 November, 2023.
Blood Cancer
 1 min.

 Published on 24/09/2024 |  Synthesis  | The ContentGeneMD editorial committee

AML Classifications: WHO vs ICC 2022 Update The following is a summary of the article “Definitions of Acute Myeloid Leukaemia and their clinical significance according to the WHO 2022 and ICC classification” by Donata Backhaus et al (University of Leipzig Medical Center, Germany), which...

 Read more